Education
About Us
Working with TipRanks
Follow Us
Ramm Pharma (TSE:RAMM)
:RAMM
RAMM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)118.29K
Market Cap
C$1.79M
Enterprise ValueC$1.07M
Total Cash (Recent Filing)C$803.88K
Total Debt (Recent Filing)C$80.39K
Price to Earnings (P/E)―
Beta-2.63
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt (debt-to-equity ~1–2%) materially reduces refinancing and interest-rate pressure, preserving financial optionality. For a cash-consuming biotech, low leverage lengthens runway, lowers insolvency risk, and gives management time to execute restructuring or commercialization initiatives without urgent debt maturities.
Reduced Cash BurnA meaningful reduction in cash burn demonstrates improved operational control or cost restructuring that extends runway. This durable improvement reduces near-term financing needs, lessens dilution risk, and improves the odds management can reach cash-neutral operations or close strategic deals over the next several quarters.
Narrowing LossesProgress toward smaller absolute losses indicates that revenue or cost actions are having effect. Sustained narrowing is a structural positive: it signals a path to breakeven and improved return metrics if maintained, and supports stronger credit and partnership prospects compared with firms still widening losses.
Bears Say
Declining RevenueAn ongoing revenue decline erodes scale and makes fixed-cost absorption harder, limiting margin recovery and cash generation. For a specialty/generic drug maker, falling sales indicate product, market-share, or demand issues that are structural unless new launches or contracts reverse the trend.
Volatile & Weak MarginsA dramatic gross-margin swing signals unstable pricing, cost of goods, or product mix and undermines earnings predictability. Margin volatility constrains reinvestment ability, makes forecasting hard for partners and lenders, and increases the likelihood that profitability will remain elusive without durable cost or pricing fixes.
Persistent Negative Cash FlowConsistent negative OCF and FCF force dependence on external financing, which can dilute shareholders or be restricted during market stress. Even with low debt, declining equity/assets and ongoing cash needs risk balance-sheet erosion and constrain strategic investments absent sustained operational turnaround.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.79M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Mar 26, 2026 which is in 11 days.
How were Ramm Pharma’s earnings last quarter?
Currently, no data Available
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---